Kolkailah AA, Lingvay I, Dobrecky-Mery I, Aharonovich A, et al. Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial. Diabetes Obes Metab 2022 Dec 13. doi: 10.1111/dom.14941.
PMID: 36514266